{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:47:38Z","timestamp":1793353658044,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jhep.2022.01.027","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T02:20:07Z","timestamp":1644632407000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-0362","authenticated-orcid":false,"given":"Peter P.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-2669","authenticated-orcid":false,"given":"Qiushi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-375X","authenticated-orcid":false,"given":"Gizem S.","family":"Nemutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-9798","authenticated-orcid":false,"given":"Ali","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Bethea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-7583","authenticated-orcid":false,"given":"Mary Linton B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-1287","authenticated-orcid":false,"given":"Brian P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed Z.","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/nutrit\/nuw063","article-title":"Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials","volume":"75","author":"Ursoniu","year":"2017","journal-title":"Nutr Rev"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib4","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2017.08.052","article-title":"Risk for hepatocellular carcinoma after hepatitis C virus antiviral therapy with direct-acting antivirals: case closed?","volume":"153","author":"Maan","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhep.2022.01.027_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21173","article-title":"Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents","volume":"3","author":"Chen","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.jhep.2022.01.027_bib8","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.cgh.2019.02.020","article-title":"For whom is hepatocellular carcinoma surveillance after sustained virologic response cost-effective?","volume":"17","author":"Singal","year":"2019","journal-title":"Clin Gastroenterol Hepatol : the official Clin Pract J of the American Gastroenterological Association"},{"issue":"9","key":"10.1016\/j.jhep.2022.01.027_bib9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.01.027_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugpo.2019.06.003","article-title":"What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada","volume":"72","author":"Krajden","year":"2019","journal-title":"Int J Drug Pol"},{"issue":"2","key":"10.1016\/j.jhep.2022.01.027_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"10179","key":"10.1016\/j.jhep.2022.01.027_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jhep.2022.01.027_bib14","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2022.01.027_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J\u00a0of Viral Hepat"},{"issue":"12","key":"10.1016\/j.jhep.2022.01.027_bib17","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/liv.15032","article-title":"Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals","volume":"41","author":"S\u00e1nchez-Azofra","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2022.01.027_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/liv.13555","article-title":"Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue","volume":"38","author":"Zhao","year":"2018","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jhep.2022.01.027_bib19","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2022.01.027_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bpg.2014.08.005","article-title":"Hepatocellular carcinoma: diagnostic criteria by imaging techniques","volume":"28","author":"Ronot","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","article-title":"Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis","volume":"30","author":"Singal","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2022.01.027_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-4733.2008.00448.x","article-title":"Mapping the English and Chinese versions of the functional assessment of cancer therapy--general to the EQ-5D utility index","volume":"12","author":"Cheung","year":"2009","journal-title":"Value in health"},{"issue":"2","key":"10.1016\/j.jhep.2022.01.027_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2050640616659024","article-title":"Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study","volume":"5","author":"El-Fattah","year":"2017","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States","volume":"50","author":"Lang","year":"2009","journal-title":"J\u00a0of Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2022.01.027_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2022.01.027_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL--EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"Llovet","year":"2012","journal-title":"J\u00a0of Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2022.01.027_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.hpb.2016.06.010","article-title":"Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors","volume":"18","author":"Sucandy","year":"2016","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.jhep.2022.01.027_bib32","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.suronc.2011.10.005","article-title":"Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment","volume":"21","author":"Toro","year":"2012","journal-title":"Surg Oncol"},{"issue":"4p2","key":"10.1016\/j.jhep.2022.01.027_bib33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","article-title":"Trends in organ donation and transplantation in the United States, 1999--2008","volume":"10","author":"Wolfe","year":"2010","journal-title":"American J of Transplant"},{"issue":"10","key":"10.1016\/j.jhep.2022.01.027_bib34","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3748\/wjg.v22.i10.2993","article-title":"Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2022.01.027_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre--and post--liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transplant"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2022.01.027_bib37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost--utility analysis","volume":"98","author":"Coon","year":"2008","journal-title":"Br J of Cancer"},{"issue":"3","key":"10.1016\/j.jhep.2022.01.027_bib38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1572-0241.2002.05557.x","article-title":"Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience)","volume":"97","author":"Trevisani","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cgh.2018.10.031","article-title":"Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis","volume":"17","author":"Choi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.26944","article-title":"Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach","volume":"59","author":"Mourad","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2022.01.027_bib41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value in Health"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"9","key":"10.1016\/j.jhep.2022.01.027_bib43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"New Engl J of Med"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib44","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/cncr.24817","article-title":"Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States","volume":"116","author":"Artinyan","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jhep.2022.01.027_bib45","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cgh.2012.11.010","article-title":"Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening","volume":"11","author":"Singal","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.01.027_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/M14-0558","article-title":"Screening for hepatocellular carcinoma in chronic liver disease: a systematic review","volume":"161","author":"Kansagara","year":"2014","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jhep.2022.01.027_bib47","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/hep.26138","article-title":"Whither hepatocellular carcinoma screening?","volume":"56","author":"Sherman","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2022.01.027_bib48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/L15-5049","article-title":"Screening for hepatocellular carcinoma in chronic liver disease","volume":"162","author":"Chirovsky","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jhep.2022.01.027_bib49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2017.19872","article-title":"Screening for cervical cancer in primary care: a decision analysis for the US preventive Services task force","volume":"320","author":"Kim","year":"2018","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.jhep.2022.01.027_bib50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/0003-4819-156-9-201205010-00002","article-title":"Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk","volume":"156","author":"van Ravesteyn","year":"2012","journal-title":"Ann of Intern Med"},{"issue":"23","key":"10.1016\/j.jhep.2022.01.027_bib51","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1001\/jama.2016.6828","article-title":"Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive Services task force","volume":"315","author":"Knudsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.01.027_bib52","series-title":"Section 5. Modeling","year":"2017"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:46:19Z","timestamp":1759175179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0168827822000745"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.01.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}